Reposted by @jp7916.bsky.social
A recent ICIJ analysis found that cancer drug companies that paid fines or made settlement payments rarely admitted to wrongdoing. Instead, if they settled, their explanations sometimes centered on wanting to avoid lengthy, expensive litigation. buff.ly/S6IdJjc
buff.ly
Big fines and settlements barely dent cancer drugmakers’ revenues, fail to deter wrongdoing - ICIJ
An ICIJ review found nearly $1.7 billion in settlements and fines over a 15 year period. But experts said many companies see the payouts as the cost of doing business.